President Biden on Oct. 26, 2022 (Oliver Contreras/Sipa USA/Sipa via AP Images)

Al­ny­lam blames the In­fla­tion Re­duc­tion Act for a PhI­II cut — would it have sold enough for ne­go­ti­a­tions?

Al­ny­lam Phar­ma­ceu­ti­cals, the phar­ma mar­ket’s leader in RNAi ther­a­pies, re­port­ed its third quar­ter earn­ings Thurs­day, up­dat­ing share­hold­ers on its pipeline progress and ini­tial sales fig­ures …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.